Table 1 Demographic and baseline data for the mild cognitive impairment group
From: For debate: substituting placebo controls in long-term Alzheimer's prevention trials
Characteristic | Value |
|---|---|
| Â | (n = 397) |
Age (years) | 74.2 (7.4) |
Women | 141 (36%) |
Apolipoprotein E4 | Â |
   0 E4 alleles | 185 (47%) |
   1 E4 allele | 165 (42%) |
   2 E4 alleles | 47 (12%) |
Education (years) | 15. 7 (3.0) |
Body mass index (kg/m2) | 26.1 (4.0) |
Hachinski modified (0 to 12) | 1 (0 to 4) |
FAQ (0 (normal) to 50) | 2 (0 to 21) |
MMSE (0 to 30 (best)) | 27.0 (1.8) |
ADAScog, modified (0 (best) to 85) | 18.6 (6.3) |
NP-Batt (z score) | -1.02 (0.66) |
Medication | 240 (60%) |
| Â | (n = 199) |
β-amyloid1-42 | 146.9 (48.3 to 298.8) |
Total tau protein | 85.6 (28.5 to 463.2) |
β-amyloid1-42/total tau protein | 1.564 (0.233 to 7.61) |